Sermorelin | Reviews, Dosage & Clinical Trials – Peptides

Effective treatment of adult-onset growth hormone insufficiency: Sermorelin is an effective and attractive treatment of adult-onset GH insufficiency. Unlike rhGH, sermorelin does not stimulate IGF-1 production in the liver and instead stimulates the pituitary gland to produce and secrete endogenous hGH, giving it a number of clinical advantages over exogenous hGH.

Notably, according to a 2006 article by Richard Walker, overdoses of endogenous hGH are difficult if not impossible to achieve as the effects of sermorelin are regulated by negative feedback involving the inhibitory neurohormone, somatostatin.

Sermorelin is not associated with the pro-cancer and pro-diabetes side effects linked to long-term hGH therapy, and is thus heavily researched to treat adult-onset GH insufficiency along with being used in longevity medicine for preserving youthful anatomy and physiology [5].

Positive effects on body composition: Sermorelin has been identified as one of several growth hormone secretagogues (GHS) that can help manage body composition in hypogonadal males. In a 2020 paper, Deepankar et al. noted that sermorelin can significantly improve body composition (in hypogonadal males) while ameliorating specific hypogonadal symptoms such as fat gain and muscular atrophy [6].

While the authors suggest that sermorelin could be used to achieve lean mass gain in both hypogonadal males and men with subclinical hypogonadism, to date, there is no published research that has investigated sermorelins effect on body composition in healthy subjects, highlighting an area for further research.

Potential anti-aging benefits: A 1992 study identified sermorelins potential anti-aging benefits after nine young male test subjects (22 to 33 years old) and ten elderly male test subjects (60 to 78 years old) were administered the peptide. The study found that short-term subcutaneous sermorelin injections enabled healthy male test subjects to reverse age-related decreases in GH and levels of IGF-I [7].

A 1997 single-blind randomized placebo-controlled trial found that elderly male and female test subjects who received nightly subcutaneous injections of sermorelin for 16 weeks experienced a significant increase in skin thickness. The peptide was found to produce significant increases in lean body mass in male test subjects and notable increases in libido and wellbeing. Male test subjects gained an average of 1.26 kg of lean body mass by the end of the trial [8]

Sermorelin and heart health: Sermorelin has been investigated alongside other GHRH agonists as a potential treatment for myocardial infarction scarring in swine [9]. The 2015 study found that sermorelin offered a number of benefits in post-heart attack animal models, which included:

As a result, there is research interest in sermorelins heart health-related benefits, namely in its potential to treat problems resulting from cardiac remodeling and ability to heal damage in myocytes following a heart attack.

Excerpt from:

Sermorelin | Reviews, Dosage & Clinical Trials - Peptides